)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Apogee Therapeutics (APGE) investor relations material
Apogee Therapeutics Citi Annual Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Citi Annual Global Healthcare Conference 2025 summary3 Dec, 2025
Key clinical milestones and data readouts
2026 will feature major clinical readouts, including accelerated timelines for lead program 777 in atopic dermatitis (AD) and asthma, with Q1 and Q2 data expected for multiple trials.
Maintenance and dose-response data for 777 in AD will inform Phase III dosing, with both three- and six-month dosing regimens being tested and optimized.
A head-to-head Phase 1b combo trial of IL-13 and OX40 ligand against Dupixent is ongoing, with results anticipated in the second half of 2026.
Asthma expansion is underway, with Phase 1b data expected in Q1 and plans to initiate Phase II later in the year.
The company aims to start Phase III trials by the end of 2026, following FDA discussions.
Differentiation and product profile
777 offers a transformative dosing schedule (every three or six months), addressing needle fatigue and injection site pain, key reasons for discontinuation of current therapies.
Rapid itch relief at 48 hours and strong EASI-75 scores position 777 as a highly preferred product among both physicians and patients.
Market research indicates high willingness among patients to switch to 777 for less frequent dosing, even among those controlled on current therapies.
The product profile is seen as the most preferred in AD, with commercial strategy focused on maintaining this differentiation.
Higher and lower dose ranges are being tested to optimize efficacy and regulatory positioning.
Market opportunity and commercial strategy
Biologic penetration in AD and asthma remains low (around 10%), presenting significant growth potential as the market expands at 25% annually.
The company expects to drive deeper biologic adoption, especially with quarterly and semi-annual dosing options.
Recent launches of competing products show strong uptake despite limited differentiation, indicating robust market demand.
Payer access is expected to be favorable, with market research showing 60% of physicians would choose 777 as their first-line biologic.
Early engagement with payers and inclusion of features like auto-injectors and prefilled syringes are designed to support broad access at launch.
777's impact on AD biologic penetration
777 asthma FeNO data: What is a win?
APG279 combo: Efficacy target vs DUPIXENT
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Apogee Therapeutics earnings date
Q4 20253 Mar, 2026
Next Apogee Therapeutics earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apogee Therapeutics Inc. (APGE) is a biotechnology company engaged in the development of differentiated biologics for the treatment of various inflammatory and immunology (I&I) diseases, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other conditions with high unmet medical needs. The company's approach is focused on creating best-in-class therapies that aim to improve upon the current standard of care for these conditions. The company is headquartered in San Francisco, California, and Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage